

VolitionRx

09:02 13 Nov 2020

VolitionRx ends 3Q with \$21M in cash as it prepares to launch Nu.Q Vet Cancer Screening Test

VolitionRx Limited (NYSEAMERICAN:VNRX) said Thursday it ended its third quarter with cash and cash equivalents of about \$21 million as it prepares to launch its first product -- the Nu.Q Vet Cancer Screening Test -- on November 30.

"We continue to manage our expenditures carefully, and as we approach launch and commercialization, our burn rate is approximately \$1.6 - \$1.7 million per month," the Belgian company said in a statement, highlighting the quarter, which ended September 30.

"During the third quarter, despite the persistence of the COVID-19 pandemic, we have made significant progress on many fronts and are on track to launch our first product, the Nu.Q Vet Cancer Screening Test, on November 30," said CEO Cameron Reynolds. "This is a pivotal moment for Volition, demonstrating that our platform has the reliability and reproducibility to launch in an independent laboratory."

READ: VolitionRx says veterinary oncology experts contribute to report ahead of Nu.Q Vet Cancer Screening Test launch

Reynolds added: "We have also made considerable progress in our human cancer program and, in particular, in blood cancer where we have obtained similar results in both humans and dogs using the same assay. Based on these promising results, we have engaged Diagnostic Oncology CRO LLC as a contract research organization to conduct a U.S. clinical trial for Non-Hodgkin's Lymphoma."

The company has high hopes for the Nu.Q Vet Cancer Screening Test, which will initially be positioned for use in the annual health check of older dogs (those that are seven years and older) and for cases where there is a high suspicion of cancer. The test will be available from the GI Lab at Texas A&M University to potentially thousands of veterinarians across Texas and the rest of the US.

Volition sees a significant potential market opportunity into the millions of tests per year as there are around 77 million dogs in the US. It said revenue is expected to be \$45 per test and generate a greater than 85% gross margin.


The test is a simple, low-cost, easy to use ELISA-based screening blood test, which will help streamline the screening process for up to one-third of cancers in dogs, including common malignancies such as lymphoma and hemangiosarcoma.

Volition cited two recent studies: In a study of over 330 dogs conducted by Texas A&M University, the test gave good clinical discrimination with an AUC of 87.3% for lymphoma and 97.6% for hemangiosarcoma. At 100% specificity, the test demonstrated detection rates of 74% of lymphoma and 89% of hemangiosarcoma.

Price: 3.78

Market Cap: \$199.3 m

1 Year Share Price Graph



March 2020 September 2020 March 2021

Share Information

Code: VNRX

Listing: NYSEMKT

52 week	High	Low
	6.66	2.22

Sector: Pharma & Biotech

Website: volitionrx.com

Company Synopsis:

*Volition is a multi-national life sciences company developing simple, easy to use blood-based cancer tests to accurately diagnose a range of cancers. The tests are based on the science of Nucleosomics®, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid -- an indication that disease is present. *

action@proactiveinvestors.com

Looking ahead, Volition said it expects to achieve the following milestones during 2020 and beyond:

- Launch of the Nu.Q Vet Cancer Screening Test in the US;
- Complete the purchase and fit-out of "Silver One," to serve as its manufacturing hub and service lab in Belgium; and
- Focus on driving revenue in the coming quarters, where possible during the pandemic, in four key areas: Nu.Q Vet products, disease monitoring tests (such as COVID-19), reagent sales, and licensing of its technology for others to commercialize.

Contact the author: patrick@proactiveinvestors.com

Follow him on Twitter [@PatrickMGraham](https://twitter.com/PatrickMGraham)

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 action@proactiveinvestors.com

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of VolitionRx named herein, including the promotion by the Company of VolitionRx in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).